Investing CRISPR and Beyond: A $12.5 Billion Genomic Medicine Sector Draws Institutional Attention as Editing Technologies Mature The Fiscalist · Jul 4, 2026
Investing Ken Griffin’s Citadel Navigates Volatile First Half With Gains Across All Major Funds The Fiscalist · Jul 3, 2026
Investing Positioning Your Portfolio Before the Next Phase of AI Spending Takes Hold The Fiscalist · Jul 2, 2026
Investing Why Investors May Want to Prioritize Bond Markets Outside the U.S. The Fiscalist · Jun 27, 2026
Investing Fed’s Higher for Longer Is Breaking the 60/40 Portfolio — Advisors Are Hunting for Alternatives The Fiscalist · Jun 26, 2026
Investing Bond ETF Flows Surge in Hunt for Yield: ‘Market Sniffing Out Something Here,’ Says BlackRock Exec The Fiscalist · Jun 26, 2026
Investing Warren Buffett’s $325 Billion Cash Pile Draws Scrutiny as Berkshire Hathaway Annual Meeting Looms The Fiscalist · Jun 25, 2026
Investing How a Trust Can Shield Your Inheritance From an Ex-Spouse’s Influence Over Your Children The Fiscalist · Jun 24, 2026
Investing SpaceX Draws Short Seller Curiosity, But Most Investors Still Fear Betting Against Musk The Fiscalist · Jun 23, 2026
Investing Your Index Fund Is Hiding a Looming Tech-Stock Risk — Here Is How to Protect Your Portfolio The Fiscalist · Jun 23, 2026
